| # | Title | Journal | Year | Citations |
|---|
| 1 | A review of central 5-HT receptors and their function | Neuropharmacology | 1999 | 2,851 |
| 2 | The metabotropic glutamate receptors: Structure and functions | Neuropharmacology | 1995 | 2,138 |
| 3 | Goal-directed instrumental action: contingency and incentive learning and their cortical substrates | Neuropharmacology | 1998 | 1,313 |
| 4 | Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine | Neuropharmacology | 1986 | 1,247 |
| 5 | CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury | Neuropharmacology | 2000 | 1,217 |
| 6 | Transport of brain-derived neurotrophic factor across the blood–brain barrier | Neuropharmacology | 1998 | 1,150 |
| 7 | Pharmacological agents acting at subtypes of metabotropic glutamate receptors | Neuropharmacology | 1999 | 1,025 |
| 8 | Structural plasticity associated with exposure to drugs of abuse | Neuropharmacology | 2004 | 1,014 |
| 9 | A systematic review on reporting and assessment of adverse effects associated with transcranial direct current stimulation | International Journal of Neuropsychopharmacology | 2011 | 892 |
| 10 | GABAA receptors: Subtypes provide diversity of function and pharmacology | Neuropharmacology | 2009 | 836 |
| 11 | Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data | Neuropharmacology | 1999 | 832 |
| 12 | Towards a glutamate hypothesis of depression | Neuropharmacology | 2012 | 831 |
| 13 | Imaging dopamine's role in drug abuse and addiction | Neuropharmacology | 2009 | 825 |
| 14 | Oxidative stress in psychiatric disorders: evidence base and therapeutic implications | International Journal of Neuropsychopharmacology | 2008 | 821 |
| 15 | Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following c fibre stimulation. | Neuropharmacology | 1987 | 787 |
| 16 | A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression | International Journal of Neuropsychopharmacology | 2008 | 781 |
| 17 | Dopamine and drug addiction: the nucleus accumbens shell connection | Neuropharmacology | 2004 | 777 |
| 18 | 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist | Neuropharmacology | 1999 | 712 |
| 19 | Mechanisms of ischemic brain damage | Neuropharmacology | 2008 | 708 |
| 20 | BDNF – a key transducer of antidepressant effects | Neuropharmacology | 2016 | 701 |
| 21 | Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier | Neuropharmacology | 2001 | 700 |
| 22 | Neuroprotection for ischemic stroke: Past, present and future | Neuropharmacology | 2008 | 672 |
| 23 | Distinctive pharmacology and kinetics of cloned neuronal Ca2+ channels and their possible counterparts in mammalian CNS neurons | Neuropharmacology | 1993 | 638 |
| 24 | Structure and function of the NMDA receptor channel | Neuropharmacology | 1995 | 616 |
| 25 | Molecular biology of 5-HT receptors | Neuropharmacology | 1994 | 608 |
| 26 | Reward and aversion in a heterogeneous midbrain dopamine system | Neuropharmacology | 2014 | 606 |
| 27 | Therapeutics of Alzheimer's disease: Past, present and future | Neuropharmacology | 2014 | 601 |
| 28 | Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse | Neuropharmacology | 2007 | 593 |
| 29 | Regulation of NMDA receptor subunit expression and its implications for LTD, LTP, and metaplasticity | Neuropharmacology | 2008 | 570 |
| 30 | Metabotropic glutamate receptors: From the workbench to the bedside | Neuropharmacology | 2011 | 559 |
| 31 | Serotonin and appetite | Neuropharmacology | 1984 | 557 |
| 32 | The Yin and Yang of dopamine release: a new perspective | Neuropharmacology | 2007 | 546 |
| 33 | Stimulation of food intake by muscimol and beta endorphin | Neuropharmacology | 1977 | 541 |
| 34 | Molecular mechanisms of drug addiction | Neuropharmacology | 2004 | 538 |
| 35 | Blood BDNF concentrations reflect brain-tissue BDNF levels across species | International Journal of Neuropsychopharmacology | 2011 | 533 |
| 36 | Cannabinoid physiology and pharmacology: 30 years of progress | Neuropharmacology | 2004 | 531 |
| 37 | A nomenclature for ligand-gated ion channels | Neuropharmacology | 2009 | 531 |
| 38 | The past, present and future of purine nucleotides as signalling molecules | Neuropharmacology | 1997 | 530 |
| 39 | Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid | Neuropharmacology | 2007 | 525 |
| 40 | The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies | Neuropharmacology | 2004 | 523 |
| 41 | Neuropeptides — an overview | Neuropharmacology | 2000 | 519 |
| 42 | A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia | International Journal of Neuropsychopharmacology | 2005 | 516 |
| 43 | Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist | Neuropharmacology | 2005 | 500 |
| 44 | Executive function and PTSD: Disengaging from trauma | Neuropharmacology | 2012 | 495 |
| 45 | Models of the diffusional spread of nitric oxide: Implications for neural nitric oxide signalling and its pharmacological properties | Neuropharmacology | 1994 | 492 |
| 46 | Targeting acetylcholinesterase and butyrylcholinesterase in dementia | International Journal of Neuropsychopharmacology | 2006 | 492 |
| 47 | BDNF-induced local protein synthesis and synaptic plasticity | Neuropharmacology | 2014 | 492 |
| 48 | Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP | Neuropharmacology | 2005 | 487 |
| 49 | Biological substrates of reward and aversion: A nucleus accumbens activity hypothesis | Neuropharmacology | 2009 | 483 |
| 50 | SB 242084, a Selective and Brain Penetrant 5-HT 2C Receptor Antagonist | Neuropharmacology | 1997 | 480 |
| 51 | Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability | Neuropharmacology | 2015 | 473 |
| 52 | Dopamine receptors and brain function | Neuropharmacology | 1996 | 469 |
| 53 | Individual differences in the attribution of incentive salience to reward-related cues: Implications for addiction | Neuropharmacology | 2009 | 469 |
| 54 | Tissue distribution of the P2X7 receptor | Neuropharmacology | 1997 | 467 |
| 55 | Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex | Neuropharmacology | 2002 | 465 |
| 56 | Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders | International Journal of Neuropsychopharmacology | 2011 | 462 |
| 57 | Signaling pathways underlying the rapid antidepressant actions of ketamine | Neuropharmacology | 2012 | 460 |
| 58 | Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review | Neuropharmacology | 2018 | 460 |
| 59 | Serotonin Induces Excitatory Postsynaptic Potentials in Apical Dendrites of Neocortical Pyramidal Cells | Neuropharmacology | 1997 | 455 |
| 60 | The GABA system in anxiety and depression and its therapeutic potential | Neuropharmacology | 2012 | 453 |
| 61 | Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines | Neuropharmacology | 1974 | 452 |
| 62 | AMPA and kainate receptors | Neuropharmacology | 1995 | 444 |
| 63 | Dopamine System Dysregulation in Major Depressive Disorders | International Journal of Neuropsychopharmacology | 2017 | 444 |
| 64 | A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression | International Journal of Neuropsychopharmacology | 2008 | 442 |
| 65 | Stress and anxiety: Structural plasticity and epigenetic regulation as a consequence of stress | Neuropharmacology | 2012 | 437 |
| 66 | Oxidative stress in Alzheimer disease: A possibility for prevention | Neuropharmacology | 2010 | 431 |
| 67 | Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonists | Neuropharmacology | 1980 | 427 |
| 68 | Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis | International Journal of Neuropsychopharmacology | 2002 | 427 |
| 69 | Kynurenine pathway metabolism and the microbiota-gut-brain axis | Neuropharmacology | 2017 | 424 |
| 70 | Regulation of Akt and glycogen synthase kinase-3β phosphorylation by sodium valproate and lithium | Neuropharmacology | 2002 | 422 |
| 71 | Growing up in a Bubble: Using Germ-Free Animals to Assess the Influence of the Gut Microbiota on Brain and Behavior | International Journal of Neuropsychopharmacology | 2016 | 419 |
| 72 | Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum | Neuropharmacology | 2010 | 415 |
| 73 | Addiction as a stress surfeit disorder | Neuropharmacology | 2014 | 415 |
| 74 | Immunohistochemical study of the P2X2 and P2X3 receptor subunits in rat and monkey sensory neurons and their central terminals | Neuropharmacology | 1997 | 404 |
| 75 | Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) | International Journal of Neuropsychopharmacology | 2019 | 404 |
| 76 | GABAergic interneuron origin of schizophrenia pathophysiology | Neuropharmacology | 2012 | 403 |
| 77 | Evidence for histaminergic arousal mechanisms in the hypothalamus of cat | Neuropharmacology | 1988 | 401 |
| 78 | The role of inflammation in epileptogenesis | Neuropharmacology | 2013 | 393 |
| 79 | Neurobiological substrates for the dark side of compulsivity in addiction | Neuropharmacology | 2009 | 390 |
| 80 | Incubation of cocaine craving after withdrawal: a review of preclinical data | Neuropharmacology | 2004 | 389 |
| 81 | Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease | Neuropharmacology | 2021 | 386 |
| 82 | Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues | Neuropharmacology | 2010 | 384 |
| 83 | Diversity of vertebrate nicotinic acetylcholine receptors | Neuropharmacology | 2009 | 383 |
| 84 | 5-HT Receptor Classification and Nomenclature: Towards a Harmonization with the Human Genome | Neuropharmacology | 1997 | 379 |
| 85 | Impaired safety signal learning may be a biomarker of PTSD | Neuropharmacology | 2012 | 378 |
| 86 | The action of sedatives on brain stem oculomotor systems in man | Neuropharmacology | 1971 | 374 |
| 87 | Differential neuronal encoding of novelty, familiarity and recency in regions of the anterior temporal lobe | Neuropharmacology | 1998 | 374 |
| 88 | LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors | Neuropharmacology | 1998 | 371 |
| 89 | The mania rating scale: Scale construction and inter-observer agreement | Neuropharmacology | 1978 | 363 |
| 90 | Neuropharmacology of AMPA and kainate receptors | Neuropharmacology | 1998 | 350 |
| 91 | The use of fura-2 for estimating ca buffers and ca fluxes | Neuropharmacology | 1995 | 348 |
| 92 | Defining post-stroke recovery: implications for design and interpretation of drug trials | Neuropharmacology | 2000 | 345 |
| 93 | Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder | International Journal of Neuropsychopharmacology | 2009 | 343 |
| 94 | Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS | Neuropharmacology | 2000 | 340 |
| 95 | Glutamate transmission in addiction | Neuropharmacology | 2009 | 340 |
| 96 | Neurobiology of ADHD | Neuropharmacology | 2009 | 339 |
| 97 | In vitro identification and electrophysiological characterization of dopamine neurons in the ventral tegmental area | Neuropharmacology | 2010 | 339 |
| 98 | Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naïve children with ADHD during a rewarded continuous performance task | Neuropharmacology | 2009 | 338 |
| 99 | Regulation of NMDA receptors by phosphorylation | Neuropharmacology | 2007 | 336 |
| 100 | Epigenetic mechanisms of drug addiction | Neuropharmacology | 2014 | 336 |
